These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 29597034)

  • 1. Microsuspension of fatty acid esters of entecavir for parenteral sustained delivery.
    Ho MJ; Lee DR; Im SH; Yoon JA; Shin CY; Kim HJ; Jang SW; Choi YW; Han YT; Kang MJ
    Int J Pharm; 2018 May; 543(1-2):52-59. PubMed ID: 29597034
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design and in vivo evaluation of entecavir-3-palmitate microcrystals for subcutaneous sustained delivery.
    Ho MJ; Lee DR; Im SH; Yoon JA; Shin CY; Kim HJ; Jang SW; Choi YW; Han YT; Kang MJ
    Eur J Pharm Biopharm; 2018 Sep; 130():143-151. PubMed ID: 29940226
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of macrophage and angiogenesis inhibition on the drug release and absorption from an intramuscular sustained-release paliperidone palmitate suspension.
    Darville N; van Heerden M; Mariën D; De Meulder M; Rossenu S; Vermeulen A; Vynckier A; De Jonghe S; Sterkens P; Annaert P; Van den Mooter G
    J Control Release; 2016 May; 230():95-108. PubMed ID: 27067365
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis and Physicochemical Evaluation of Entecavir-Fatty Acid Conjugates in Reducing Food Effect on Intestinal Absorption.
    Jung HJ; Ho MJ; Ahn S; Han YT; Kang MJ
    Molecules; 2018 Mar; 23(4):. PubMed ID: 29565327
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-Acting Diclofenac Ester Prodrugs for Joint Injection: Kinetics, Mechanism of Degradation, and In Vitro Release From Prodrug Suspension.
    Mertz N; Larsen SW; Kristensen J; Østergaard J; Larsen C
    J Pharm Sci; 2016 Oct; 105(10):3079-3087. PubMed ID: 27475785
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intramuscular administration of paliperidone palmitate extended-release injectable microsuspension induces a subclinical inflammatory reaction modulating the pharmacokinetics in rats.
    Darville N; van Heerden M; Vynckier A; De Meulder M; Sterkens P; Annaert P; Van den Mooter G
    J Pharm Sci; 2014 Jul; 103(7):2072-2087. PubMed ID: 24845884
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of particle size on in vivo performances of long-acting injectable drug suspension.
    Ho MJ; Jeong MY; Jeong HT; Kim MS; Park HJ; Kim DY; Lee HC; Song WH; Kim CH; Lee CH; Choi YW; Choi YS; Han YT; Kang MJ
    J Control Release; 2022 Jan; 341():533-547. PubMed ID: 34902451
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An injectable liquid crystal system for sustained delivery of entecavir.
    Lim JL; Ki MH; Joo MK; An SW; Hwang KM; Park ES
    Int J Pharm; 2015 Jul; 490(1-2):265-72. PubMed ID: 26004002
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lipophilic nalmefene prodrugs to achieve a one-month sustained release.
    Gaekens T; Guillaume M; Borghys H; De Zwart LL; de Vries R; Embrechts RC; Vermeulen A; Megens AA; Leysen JE; Herdewijn P; Annaert PP; Atack JR
    J Control Release; 2016 Jun; 232():196-202. PubMed ID: 27107723
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nano- and microcrystals of griseofulvin subcutaneously administered to rats resulted in improved bioavailability and sustained release.
    Sigfridsson K; Rydberg H; Strimfors M
    Drug Dev Ind Pharm; 2019 Sep; 45(9):1477-1486. PubMed ID: 31260340
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro and in vivo assessment of the abuse potential of PF614, a novel BIO-MD™ prodrug of oxycodone.
    Kirkpatrick DL; Schmidt WK; Morales R; Cremin J; Seroogy J; Husfeld C; Jenkins T
    J Opioid Manag; 2017; 13(1):39-49. PubMed ID: 28345745
    [TBL] [Abstract][Full Text] [Related]  

  • 12. OAT1 and OAT3: targets of drug-drug interaction between entecavir and JBP485.
    Xu Q; Wang C; Meng Q; Liu Q; Sun H; Peng J; Ma X; Kaku T; Liu K
    Eur J Pharm Sci; 2013 Mar; 48(4-5):650-7. PubMed ID: 23313623
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic studies in animals of a new parenteral penem CP-65,207 and its oral prodrug ester.
    Gootz T; Girard D; Schelkley W; Tensfeldt T; Foulds G; Kellogg M; Stam J; Campbell B; Jasys J; Kelbaugh P
    J Antibiot (Tokyo); 1990 Apr; 43(4):422-32. PubMed ID: 2351614
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Entecavir pharmacokinetics, safety, and tolerability after multiple ascending doses in healthy subjects.
    Yan JH; Bifano M; Olsen S; Smith RA; Zhang D; Grasela DM; LaCreta F
    J Clin Pharmacol; 2006 Nov; 46(11):1250-8. PubMed ID: 17050790
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro and in vivo release of dinalbuphine sebacate extended release formulation: Effect of the oil ratio on drug release.
    Li CJ; Ku MY; Lu CY; Tien YE; Chern WH; Huang JD
    Int J Pharm; 2017 Oct; 531(1):306-312. PubMed ID: 28847670
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A validated method for quantifying entecavir in biological matrices and its application in a pharmacokinetic study in rats and dogs.
    Huang X; Jiang ZZ; Tang WW; Xiao Y; Zhang LY; Zhang ZJ
    Drug Res (Stuttg); 2013 Dec; 63(12):644-9. PubMed ID: 24203082
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diclofenac-β-cyclodextrin for colonic drug targeting: In vivo performance in rats.
    Vieira AC; Serra AC; Veiga FJ; Gonsalves AM; Basit AW; Murdan S
    Int J Pharm; 2016 Mar; 500(1-2):366-70. PubMed ID: 26784980
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A candidate drug administered subcutaneously to rodents as drug particles showing hepatic recirculation which influenced the sustained release process.
    Sigfridsson K; Arvidsson T; Xue A; Wagner DJ; Pop-Damkov P; Zhang G; Strimfors M
    Int J Pharm; 2020 May; 581():119252. PubMed ID: 32240808
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of a Physiologically Relevant Population Pharmacokinetic in Vitro-in Vivo Correlation Approach for Designing Extended-Release Oral Dosage Formulation.
    Kim TH; Shin S; Bulitta JB; Youn YS; Yoo SD; Shin BS
    Mol Pharm; 2017 Jan; 14(1):53-65. PubMed ID: 27809538
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro and in vivo evaluations of the metabolism, pharmacokinetics, and bioavailability of ester prodrugs of L-767,679, a potent fibrinogen receptor antagonist: an approach for the selection of a prodrug candidate.
    Prueksaritanont T; Gorham LM; Breslin MJ; Hutchinson JH; Hartman GD; Vyas KP; Baillie TA
    Drug Metab Dispos; 1997 Aug; 25(8):978-84. PubMed ID: 9280406
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.